Kite Pharma (KITE): Zuma-1 Debate Not Significant - Jefferies

November 23, 2016 6:58 AM EST
Get Alerts KITE Hot Sheet
Price: $53.62 +5.63%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade KITE Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after a debate over pot'l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics occurred around the word "relapsed".

The analyst believes little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed patients are healthier than refractory patients. Analysis suggests otherwise and we think FDA should come to a similar conclusion.

No change to the price target of $72.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $51.69 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment